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Abstract: Assessing outcomes in multinational studies on traumatic brain injury (TBI) poses major
challenges and requires relevant instruments in languages other than English. Of the 19 outcome
instruments selected for use in the observational Collaborative European NeuroTrauma Effective-
ness Research in TBI (CENTER-TBI) study, 17 measures lacked translations in at least one target
language. To fill this gap, we aimed to develop well-translated linguistically and psychometrically
validated instruments. We performed translations and linguistic validations of patient-reported
measures (PROMs), clinician-reported (ClinRO), and performance-based (PerfO) outcome instru-
ments, using forward and backward translations, reconciliations, cognitive debriefings with up to
10 participants, iterative revisions, and international harmonization with input from over 150 interna-
tional collaborators. In total, 237 translations and 211 linguistic validations were carried out in up to
20 languages. Translations were evaluated at the linguistic and cultural level by coding changes when
the original versions are compared with subsequent translation steps, using the output of cognitive
debriefings, and using comprehension rates. The average comprehension rate per instrument varied
from 88% to 98%, indicating a good quality of the translations. These outcome instruments provide a
solid basis for future TBI research and clinical practice and allow the aggregation and analysis of
data across different countries and languages.
Keywords: translation; linguistic validation; outcome instruments; traumatic brain injury
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1. Introduction
Traumatic brain injury (TBI) is a major cause of lifelong disability worldwide [1].
It is defined as “an alteration in brain function, or other evidence of brain pathology,
caused by an external force” [2] (p. 1637). A TBI may result in a variety of consequences,
such as temporary or persisting functional disability [3]; neurological problems [4,5],
including sensory-motor disorders [6,7], as well as neuropsychological [8,9], psychosocial,
and psychiatric sequelae [10–12]; and reduced health-related quality of life (HRQOL) [13].
Given the broad range of areas affected, the complexity and heterogeneity of TBI
and its consequences cannot be adequately captured by unidimensional outcome assess-
ments [14]. The paradigm shift in classifying and treating TBI not only as an acute but
rather as a chronic brain disease emphasizes the need for a multi-level outcome assess-
ment [1,15,16], which should cover the various outcome domains and reflect the perspec-
tives of both patients and healthcare professionals.
Over the past 35 years, outcome instruments have been developed for different
clinical fields [17,18] and, during the last decade, TBI research has started to apply combi-
nations of them [13,14,19]. Outcomes after TBI can be assessed using instruments based
on clinician-reported outcomes (ClinROs), patient-reported outcomes measures (PROMs),
and performance-based physical and cognitive outcomes (PerfOs). PROMs use patients’
self-ratings regarding their subjective perspective of their health condition and/or medical
treatment [20,21]. In ClinRO instruments and clinical tests, the patients’ status is assessed
by trained healthcare professionals, while PerfO instruments capture the “objective” func-
tional performance through standardized tests, mostly carried out by psychologists or
other clinical personnel [21].
Multicenter multinational studies that investigate outcomes multidimensionally by
using these types of instruments are required to comprehensively characterize outcome
and recovery trajectories after TBI. A prerequisite for reliable and valid national and in-
ternational multidimensional investigations of outcomes after TBI is the availability of
well-translated, linguistically validated, and internationally harmonized ClinRO, PerfO in-
struments, and PROMs to assess cognitive, psychological, and psychosocial outcomes,
HRQOL, recovery, and amnesia in multiple languages. Many of these are, however,
only available in a limited number of languages [22].
To overcome this limitation, the instruments need to be translated and linguistically
validated in the target languages for international studies on TBI outcome. The linguistic
validation of instruments is challenging as it needs to address the cultural and conceptual
differences between the respective language while maintaining the contents of each in-
strument on a conceptual level across the different languages [23]. A systematic review
found that no standardized international guidelines exist for the linguistic validation of
health-related outcome instruments [24]. Nevertheless, several guidelines and recommen-
dations for iterative translation procedures are in use, published by the MAPI Research
Trust [25], the International Society for Pharmacoeconomics and Outcomes Research (IS-
POR) [26,27], and others [23,28,29]. Moreover, further research is addressing the issue of the
cross-linguistic adaptation of PROMs [26], ClinRO and PerfO instruments [30], and clinical
ratings (e.g., Reference [31]). To date, general principles include the following steps:
First, the team coordinating the translation of an instrument should identify and
clarify the concepts behind the instructions, items, and response formats (together with the
developer) [25]. The translation of the original instrument into the target language should
be performed by two independent native speakers, living in the country, fluent in English,
briefed concerning the translation of health-related outcome instruments, and ideally hav-
ing already performed this kind of translation before [25,26]. Second, the two translations
should be combined to form a single forward version [25,28]. This reconciled version
is back-translated by one independent linguist—a native speaker in the language of the
original instrument and fluent in the target language—living in the respective country [24].
The reconciled target version is then revised considering the backward translation. Third,
the target version should be cognitively debriefed in five to ten patients [25]. The amend-
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ments suggested by the target language translators are reviewed by the language translation
coordinating team, discussed with the team and the target language translators (and the
developer); then the translated instrument is finalized [25]. Finally, if an instrument is si-
multaneously translated into several languages, these translations should be internationally
harmonized to ensure they are comparable, a process that is performed in the translation
coordinating center together with the instrument’s authors [24]. These steps are meant to
ensure that an instrument translation is “conceptually and linguistically equivalent to the
source measure and allows data pooling and analysis/comparison across countries” [25]
(p. 21).
While designing the Collaborative European NeuroTrauma Effectiveness Research
study (CENTER-TBI; EC grant 602150; clinicaltrials.gov NCT02210221), a large interna-
tional observational European study on TBI, we found that 17 of the 19 selected instruments
or subtests were not available in at least one target language. To deal with this challenge,
we decided to conduct translations and linguistic validations of these outcome instruments
into up to 20 target languages, following most of the recommendations mentioned above.
These translated instruments have been made available to the international scientific and
clinical community. The present study describes the first part of the linguistic validation
process of the outcome instruments administered in the CENTER-TBI study. The second
part, concerning the psychometric properties of the PROMs is also published in the same
issue of this journal [32].
2. Methods
2.1. Languages
The CENTER-TBI study was conducted from 2015 to 2017, across 18 countries in
Europe and in Israel. The study protocol has been published and descriptive results have
been presented [33,34]. The target languages for the linguistic validation were determined
by the language(s) spoken in those countries that had expressed an interest in participating
(Table 1).
Table 1. Target languages for the linguistic validation of the countries that participated in the
CENTER-TBI study.




4 Czech Czech Republic
5 Danish Denmark
6 Dutch Belgium, the Netherlands
7 Finnish Finland
8 French Belgium, France












Note. As the Bulgarian and Czech centers dropped out of the CENTER-TBI study early on, not all linguistic
validation steps could be performed (see results and discussion). Moreover, cognitive debriefings were not carried
out for the Arabic and Russian language. Thus, these languages are not available on the CENTER-TBI website,
but from nvsteinbuechel@med.uni-goettingen.de for further linguistic validation.
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2.2. Instruments
The selection of the outcome instruments was informed by the Common Data Ele-
ments (CDE) recommendations [35,36] taking into consideration TBI specificity and the free
availability of instruments. As a result, the following outcome instruments were adminis-
tered in the CENTER-TBI study (see Table 2). For a detailed description, see Appendix B.
Table 2. Outcome instruments administered in the CENTER-TBI study.
Abbreviation Instrument Outcome Domain No. of Items Response Format Response Categories
clinician-reported outcome instrument (ClinRO), its questionnaire version, and a clinical amnesia test
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“a mild problem”
“a moderate problem”
“a severe problem” and
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same scale
QOLIBRI
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Table 2. Cont.
Abbreviation Instrument Outcome Domain No. of Items Response Format Response Categories
QOLIBRI-OS *










SF-36v2 Short Form HealthSurvey—Version 2 [47] Generic HRQOL 36 items Polytomous




SF-12v2 * 12-Item Short FormSurvey—Version 2 [48] Generic HRQOL 12 items Polytomous

















RAVLT Rey Auditory VerbalLearning Test [50]
Neuropsychological
outcome - -
Three versions of two
respective word lists,
15 words each (A and B,
four versions of the
instrument for repeated
testing)
TMT-A, B Trail-Making Test A,B [51]
Neuropsychological
outcome - -
TMT-A: numbers from 1
to 25
TMT-B: letters (A–L) and
numbers (1–13)
* Instruments marked with an asterisk were selected as core instruments of the CENTER-TBI study [33]. ** For the computer-based
CANTAB tests, the instructions and procedure descriptions were subjected to translation. The responses are language free as the test
battery consists of visual and auditory stimuli to which subjects react on the behavioral level: RTI = reaction time, SWM = spatial working
memory, PAL = paired associate learning, RVP = rapid visual processing, AST = attention switching task, SOC = stockings of Cambridge.
HRQOL = health-related quality of life. Bold was used to highlight the number of items in the questionnaire.
2.3. Translation and Linguistic Validation Procedure
Outcome instruments were identified for which published translations and linguistic
validations were not available in the languages required for the countries participating
in the CENTER-TBI study. For these instruments, translations and linguistic validations
were performed between October 2013 and October 2015. Table 3 gives an overview of
the pre-existing translations and the translated and linguistically validated versions in the
target languages of the participating countries.
J. Clin. Med. 2021, 10, 2863 6 of 31
Table 3. Pre-existing translations and translated and linguistically validated versions in the target languages of the participating countries.
ClinRO, Its Questionnaire









































































No. Language T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV





X X X X X X X X - - X X X X X X X X - - - - X X X X 1,3,4,5,6 1,3,4,5,6
3 Bulgarian X X X - - - - X X X X - - - - X X 1,2,3,4,5,6
4 Czech X X X - - - - X X X X - - - - X - - 1,4,5
5 Danish - - X X X X - - - - X X - - - - - - - - - - X X - - 1,2,3,4,5,6 1,2,3,4,5,6
6 Dutch - - X X X X - - - - X X X X - - - - - - - - X X X X 1,3 1,3
7 Finnish - - X X X X - - - - X X X X - - - - - - - - X X X X 1,2,3,4,5,6 1,2,3,4,5,6
8 French - - X X X X - - - - X X X X - - - - - - - - X X X X 1,3 1,3
9 German - - X X X X - - - - X X - - - - - - - - - - X X X X 1 1
10 Hebrew X X X X X X - - - - X X X X X X X X - - - - X X X X 1,3,4,5,6 1,3,4,5,6
11 Hungarian X X X X X X - - - - X X X X X X X X - - - - X X X X 1,3,4,5,6 1,3,4,5,6
12 Italian X X X X X X - - - - X X X X - - - - - - - - X X X X 1,3 1,3
13 Latvian X X X X X X X X X X X X X X X X X X - - - - X X X X 1,2,3,4,5,6 1,2,3,4,5,6
14 Lithuanian X X X X X X - - - - X X X X X X X X - - - - X X X X 1,2,3,4,5,6 1,2,3,4,5,6
15 Norwegian - - X X X X - - - - - - - - - - - - - - - - X X X X 1,2,3,4,5,6 1,2,3,4,5,6
16 Romanian X X X X X X - - - - X X X X X X X X - - - - X X X X 1,2,4,5 1,2,4,5
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Table 3. Cont.
ClinRO, Its Questionnaire









































































No. Language T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV T LV
17 Russian (forIsrael) X X X X X X - - - - X X X X X X X X - - - - X X X X 1,4,5 1,4,5
18 Slovakian X X X X X X - - - - X X X X X X X X - - - - X X X X 1,4,5 1,4,5
19 Spanish X X X X X X - - - - X X X X X X X X - - - - X X X X 1 1
20 Swedish X X X X X X - - - - X X X X - - - - - - - - X X - - 1,2,3,4,5,6 1,2,3,4,5,6
Note: X = instruments translated and linguistically validated for the CENTER-TBI study; — = already existing translated and linguistically validated instruments; empty cells or missing CANTAB subtests
numbers = no linguistic validation was performed; numbers for CANTAB subtests = already existing translations. * Instruments marked with an asterisk were selected as core instruments (GOSE, QOLIBRI-OS,
SF-12v2) [30], complemented by the GOSE-Q, the PCL-5, and the QOLIBRI, and were translated by two translators and cognitively debriefed. ClinROs = clinician-reported outcome instrument; PROMs = patient-
reported outcome measures; PerfOs = performance-based outcome instruments; T = translation steps performed; see Figure 1 (for Arabic and Russian, all steps except for cognitive debriefing were performed;
for Bulgarian, all instruments underwent at least the first harmonization; for Czech, only forward translations were carried out); LV = linguistic validation; GOSE = Glasgow Outcome Scale—Extended;
GOSE-Q = Glasgow Outcome Scale—Extended questionnaire version; GOAT = Galveston Orientation Amnesia Test; GAD-7 = Generalized Anxiety Disorder 7 Items Questionnaire; PHQ-9 = Patient Health
Questionnaire 9; PCL-5 = Posttraumatic Stress Disorder Checklist; RPQ = Rivermead Post-Concussion Symptoms questionnaire; QOLIBRI = Quality of Life after Brain Injury Scale; QOLIBRI-OS = Quality of Life
after Brain Injury—Overall Scale; SF-36v2 = Short Form Health Survey—Version 2; SF-12v2 = 12-Item Short Form Survey—Version 2; RAVLT = Rey Auditory Verbal Learning Test; TMT-A/B = Trail-Making Test
A, B; CANTAB = Cambridge Neuropsychological Test Automated Battery; (1) RTI = reaction time, (2) SWM = spatial working memory, (3) PAL = paired associate learning, (4) RVP = rapid visual processing,
(5) AST = attention switching task, (6) SOC = stockings of Cambridge.
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Figure 1. Translation and linguistic validation process.
The translations and linguistic validations of all instruments were coordinated by the
core team of the University Medical Center Göttingen (UMG), consisting of one project
coordinator and seven language coordinators, who led one to three translation teams in the
participating countries. The core team included individuals whose language proficiency
covered all required languages. In addition, the core team included at least one native
speaker of each target language who was also fluent in English and who was responsible
for that language. The core team and the translation teams in the participating countries
comprised physicians, psychologists, teachers, linguists, nurses, occupational therapists,
certified translators, administrative personnel, teachers, etc., who were experienced either
in TBI research or clinical practice, outcome measurements, and/or translation.
We used a linguistic validation procedure that was guided by the recommendations of
the MAPI Research Trust [24,25], adapted to the conditions of CENTER-TBI. As for various
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reasons (e.g., some centers dropped out of the study), some translations could not follow
the entire process, we distinguish between translation, linguistic validation (without cognitive
debriefings), and full linguistic validation (including cognitive debriefings). The outcome
instruments were divided into two groups: (1) the core instruments (GOSE, QOLIBRI-OS,
and SF-12v2) complemented by the additionally prioritized instruments (i.e., GOSE-Q,
PCL-5, and QOLIBRI) and (2) the other instruments (GOAT, GAD-7, PHQ-9, RPQ, SF-36v2,
RAVLT, TMT-A, B, and CANTAB). The procedure differed slightly for the two groups (see
Phase 2).
2.3.1. Phase 1—Conceptual Analysis of the Original Instrument
A concept list was devised as a basis for the translations, enumerating difficulties
encountered during the prescreening of the instruments, to ensure that every translator
was familiar with the constructs used in the instruments (i.e., for the GOSE, GOSE-Q,
GOAT, PCL-5, RPQ, QOLIBRI/QOLIBRI-OS, and RAVLT). This list included explanations
concerning the translation of English idioms, words with multiple meanings, symptoms,
and their intensity. For example, the item “As a result of your injury are there now
problems in how you get on with friends or relatives?” from the GOSE-Q was explained by
noting that in this context “get on” means “get along with”. The item “Being ‘superalert’
or watchful or on guard” from the PCL-5 was explained as meaning very or extremely
attentive. Moreover, translators were instructed to translate the Likert response scales
considering the hierarchical order of the answers (e.g., from “not at all” to “extremely”)
and their equidistance, etc. Concerning the PerfOs, some of the examples are presented
here. For the RAVLT, translators were encouraged to use culturally adapted translations
for the word “church”. Furthermore, this memory test includes homonyms, for which
explanations were given, e.g., earth—the planet; turkey—the animal; orange—the fruit,
etc. To further facilitate the comparability of the different RAVLT language versions,
translators were asked to use a frequency list of words for each language (e.g., http:
//corpus.rae.es/lfrecuencias.html (accessed on 16 April 2021) for Spanish) to ensure that
words with comparable frequencies were used. These strategies were adopted to support
the comparability of the different language versions.
The explanatory concept list was discussed with all translation teams in the target
languages/countries. In case of conceptual problems, the authors of the instruments
were contacted.
2.3.2. Phase 2—Translation: Forward Translations, Reconciled Version, and Backward
Translation
All the original instruments were available at least in English. For the GAD-7 and PHQ-
9, translations and validations had already been published in (most of) the target languages
and were freely available (https://www.phqscreeners.com (accessed on 16 April 2021)).
Licenses for the use of the SF-36v2, SF-12v2 were obtained from Optum [52]. Thus, the GAD-
7, PHQ-9, and SF-36v2/-12v2 were administered as such. For the GOSE, GOSE-Q, PCL-5,
QOLIBRI, and QOLIBRI-OS, two independent forward translations were performed into
several target languages by native speakers. The respective translations were reconciled
into one version by the translation team in the target language. These reconciled versions
were then revised and adapted by the core team, in agreement with the target language
translation team. A native English speaker who was not familiar with the original English
instrument translated the harmonized forward translation back into English.
All other instruments (i.e., GAD-7, PHQ-9, RPQ, RAVLT, TMT-A,B, and CANTAB
subtests) underwent a single forward translation, due to limited resources. The test
materials for the PerfO instruments comprise examples, visual and auditory materials
which were—where appropriate—also subjected to the translation procedure. The other
steps described above were the same for all instruments. See Figure 1 for an overview.
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2.3.3. Phase 3—Revision of the Forward and Backward Translations
A review of the original instrument, the forward translation(s), the reconciled version,
and the backward translation was carried out by the core team. Reconciled versions were
then agreed upon together with the translation teams in the target language countries.
2.3.4. Phase 4—Cognitive Debriefing
These interviews, referred to as cognitive debriefings, are based on detailed structured
questions whereby all answers are recorded. In the structured interview, participants were
asked to share their thoughts about the meaning of each word, phrase, and item, and to
comment on their comprehension of the respective instrument. The goal of a cognitive
debriefing is to determine whether participants understand the text in the same way as it is
intended in the original version of the instrument and whether its translation is culturally
appropriate. These cognitive debriefings were performed in three to five individuals after
TBI. Before this, three to five healthy individuals participated in the cognitive debriefings
to anticipate and modify possible semantic, syntactical, idiomatic/pragmatic, and cultural
issues early in the process. Clinicians were interviewed for the ClinROs.
The results were transcribed and translated into English by the translation teams.
When linguistic and cultural problems were identified, the translations were further modi-
fied. The GOSE, the GOSE-Q, PCL-5, QOLIBRI, and QOLIBRI-OS underwent cognitive
debriefings, which resulted in a full linguistic validation. No cognitive debriefings were
performed for the other instruments (linguistic validation).
2.3.5. Phase 5—Review of Cognitive Debriefing
The results of the cognitive debriefings were reviewed in the target languages by the
core and the translation teams: if there were linguistic and/or cultural issues, alternative
wording suggested by the lay people and patients interviewed (or clinicians, in case of
clinical ratings) was integrated into an updated version of the instrument.
2.3.6. Phase 6—International Harmonization
Final harmonization was performed by the core team for all the instruments. Fur-
thermore, telephone or video conferences were held with the target language translation
centers. In these, all concepts, such as cultural and linguistic equivalence, and all for-
mal aspects were again discussed in detail, and if necessary appropriate adjustments
were made. These versions were proofread by informed native speakers (investigators,
participants, and management committee [MC] members of the CENTER-TBI study) for
final adjustments.
2.3.7. Step 7—Final Version
Based on the revisions and results of the international harmonization, a final version
of each of the instruments was produced.
2.4. Evaluation of Translations
The comparability of the translations was assessed by numerically coding any seman-
tic, cultural, idiomatic/pragmatic, and syntactic/grammatical differences, first comparing
the original instrument version with the first harmonized version and then comparing this
with the internationally harmonized final version. This coding procedure was designed to
examine whether the translations captured the original instruments as closely as possible.
The semantic level included all changes and problems related to the meaning of words and
use of vocabulary. Cultural differences reflected the cultural relevance of the translations
in the respective target languages. Idiomatic/pragmatic issues dealt with the translation of
English idioms into the target language, for example. Finally, the syntactic/ grammatical
level included, e.g., sentence structure, punctuation, etc. To quantify the changes, we as-
sessed the differences in the instructions, items, and response categories of the instruments
at these four levels. The number of differences is expressed as a percentage (i.e., number of
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differences relative to the total number of text elements in question). This number varies
from 0% (no differences at all) to a maximum of 900% (multiple differences). Values above
100% indicate multiple modifications in one text element (e.g., nine coded differences in
one instruction are expressed as 900%). The same modification in the same item text is
considered once (e.g., the use of the courtesy pronoun in ten items of an instrument is
counted as one modification). To summarize the results, we have provided an average
percentage of changes across the languages for each instrument. To avoid the influence
of outliers (e.g., extensive number of changes in a few languages), mean and median
percentages of coded differences are reported.
Additionally, we have reported issues identified in the cognitive debriefings using
comprehension rates. These were calculated by taking the number of individuals who par-
ticipated in the cognitive debriefings, who had no problems understanding the instructions,
items, and responses, and who had no concerns regarding the phrasing and the cultural
conformance, and dividing this number by the overall number of interviewees. Mean com-
prehension rates were evaluated using quartiles, a commonly used measure in health
sciences providing information about the center and the spread of the data. A rate of 100%
indicates full comprehension, values above 75% were considered good, values ranging
from 25% to 75% acceptable, and values below 25% indicated poor understanding. The re-
sults of the cognitive debriefings and reports on the translational and linguistic validation
issues and solutions informed further revisions and harmonization of the instruments.
To assess these issues, the following questions were asked about the instructions,
each item, and the respective response categories:
1. Did you have difficulties understanding this instruction/the question/the response options?
2. What did you understand this to mean?
3. Is it relevant for your situation?
4. Are the response options clear and consistent with the question?
5. If anything was misleading or unclear, how would you reword it?
3. Results
In total, 237 translations and 211 linguistic validations were carried out in up to 20 lan-
guages, including 14 translations and 12 linguistic validations of one ClinRO, 20 translations
and 18 linguistic validations of its questionnaire version, 20 translations and 18 linguistic
validations of the clinical amnesia test, 63 translations and 55 linguistic validations of
the six PRO instruments, and 120 translations and 108 linguistic validations of the PerfO
instruments (see Table 4).
Table 4. Translations, linguistic and full linguistic validations for the instruments administered in the CENTER-TBI study.
Instrument Translations Linguistic Validations Full Linguistic Validations(Including Cognitive Debriefings)
N % N % N %
ClinRO, its questionnaire version,
and a clinical amnesia test 54 100% 48 89% 26 54%
GOSE 14 100% 12 86% 10 83%
GOSE-Q 20 100% 18 90% 16 89%
GOAT 20 100% 18 90% - -
PROMs 63 100% 55 87% 31 56%
GAD-7 2 100% 2 100% - -
PHQ-9 1 100% 1 100% - -
PCL-5 19 100% 17 89% 15 88%
RPQ 17 100% 15 88% - -
QOLIBRI 12 100% 10 83% 8 80%
QOLIBRI-OS 12 100% 10 83% 8 80%
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Table 4. Cont.
Instrument Translations Linguistic Validations Full Linguistic Validations(Including Cognitive Debriefings)
N % N % N %
PerfOs 120 100% 108 90% - -
CANTAB 83 100% 74 89% - -
RAVLT 20 100% 18 90% - -
TMT-A, B 17 100% 16 94% - -
Total 237 100% 211 89% 57 27%
Note: N = number of translations or linguistic validations, % = percentage, “-” = no translation or linguistic validation performed.
Translations = overall number and percentage of performed translations; linguistic validation = overall number of performed linguistic
validations and percentage in relation to all established translations; full linguistic validations include cognitive debriefings, linguistic
validations do not; here, the overall number of full linguistic validations performed and percentage in relation to all performed linguistic
validations is reported. Bold are for better readability.
3.1. Forward and Backward Translations, Comparison between the Original Version and the First
Harmonization (Phases 2 and 3)
The forward and backward translations were performed for all outcome instruments.
Some GOSE-Q translations conducted for the European multi-center Eurotherm study [53]
were used as the forward translation (Dutch, German, French, Hungarian, Italian, Lithua-
nian, Russian, and Spanish). All instruments were then back-translated. Already existing
and published translations of the Dutch and French GOSE, and the French translations of
the QOLIBRI/QOLIBRI-OS were edited according to the comments of the translators and
revised in an iterative process during the international harmonization (Phase 6).
The comparison between the original English versions and the first harmonization
mainly revealed differences at the semantic level, followed by idiomatic and cultural
issues (see Table 5). Considering both the mean and median percentage of differences,
most changes were observed for the RPQ, followed by the GOSE-Q, GOSE, PCL-5, and
the RAVLT.
Table 5. Average (mean and median) number of differences between the original English version and the first harmo-
nized version.
Average Number of Changes
Mean Median
Measure Text Elements No. S C I/P S/G S C I/P S/G
ClinRO, Its Questionnaire Version, and a Clinical Amnesia Test
GOSE
(10 translations)
In 11 47 3% 5% 9% 46% 0% 5% 0%
I 19 24% 2% 4% 7% 17% 0% 0% 5%
R 15 17% 1% 5% 2% 13% 0% 0% 0%
GOSE-Q
(16 translations)
In 2 97% 22% 20% 23% 50% 0% 0% 0%
I 14 18% 8% 7% 6% 14% 7% 4% 3%
R 42 9% 1% 3% 3% 2% 0% 1% 0%
GOAT
(16 translations)
In 8 13% 2% 8% 10% 6% 0% 0% 0%
I 13 11% 4% 5% 3% 8% 0% 0% 0%




In 1 0% 50% 0% 0% 0% 50% 0% 0%
I 7 0% 0% 0% 0% 0% 0% 0% 0%
R 5 0% 0% 0% 0% 0% 0% 0% 0%
PHQ-9
(1 translation)
In 1 0% 100% 0% 0% 0% 100% 0% 0%
I 10 0% 10% 0% 0% 0% 10% 0% 0%
R 5 0% 0% 0% 0% 0% 0% 0% 0%
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Table 5. Cont.
Average Number of Changes
Mean Median
Measure Text Elements No. S C I/P S/G S C I/P S/G
PCL-5
(15 translations)
In 1 60% 20% 0% 20% 0% 0% 0% 0%
I 21 19% 2% 8% 7% 14% 0% 0% 5%
R 5 12% 0% 3% 0% 0% 0% 0% 0%
RPQ
(13 translations)
In 1 146% 46% 31% 46% 146% 0% 0% 0%
I 17 10% 2% 1% 3% 6% 0% 0% 0%
R 5 14% 0% 2% 3% 20% 0% 0% 0%
QOLIBRI
(8 translations)
In 7 22% 7% 11% 25% 18% 0% 5% 29%
I 37 10% 1% 4% 6% 5% 0% 5% 7%
R 5 3% 0% 0% 0% 0% 0% 0% 0%
QOLIBRI-OS
(8 translations)
In 1 50% 50% 25% 75% 0% 0% 0% 88%
I 6 8% 0% 4% 2% 4% 0% 0% 0%




In 5 71% 13% 11% 33% 60% 0% 0% 0%
I 45 7% 0% 1% 0% 6% 0% 0% 0%
R - - - - - - - - -
TMT A/B
(14 translations)
In 6 58% 11% 17% 12% 42% 17% 8% 14%
I 38 1% 0% 0% 0% 0% 0% 0% 0%
R - - - - - - - - -
Note: No. = Number of text elements; In = Instructions: average number of modifications between the original English version and
the first harmonization (average in %, i.e., number of differences in relation to the total number of the respective text elements divided
by the number of translations); I = Items: modifications in items; R = Response categories: modifications (if applicable, otherwise “-“);
S/G = Syntactic/Grammatical level; C = Cultural level; I/P = Idiomatic/Pragmatic; ClinRO = clinician-reported outcome instrument;
PROMs = patient-reported outcome measures; PerfOs = performance-based outcome instruments; GOSE = Glasgow Outcome Scale—
Extended; instructions of the GOSE include introduction (1), commentary on the questions (9), and scoring (1); GOSE-Q = Glasgow
Outcome Scale—Extended questionnaire version; instructions include introduction and header (1) and explanatory example for the item
9; different types of responses (dichotomous yes/no and polytomous item-related responses) result in 42 elements; GOAT = Galveston
Orientation Amnesia Test (no response categories); GAD-7 = Generalized Anxiety Disorder 7 Items Questionnaire; PHQ-9 = Patient Health
Questionnaire 9 Items; PCL-5 = Posttraumatic Stress Disorder Checklist; RPQ = Rivermead Post-Concussion Symptoms questionnaire;
QOLIBRI = Quality of Life after Brain Injury Scale; instructions to the two parts (2) and five subscales (5); QOLIBRI-OS = Quality of
Life after Brain Injury—Scale; RAVLT = Rey Auditory Verbal Learning Test; here, words are treated as items (5 × 15 = 45) (no response
categories); instructions: introduction (1), explanations on the three trials (3), and the summary table for evaluation of the test result (1);
TMT-A/B = Trail-Making Test A, B; in the TMT-A/B, letters and numbers are treated as items, there are no response categories; instructions
of the TMT-A, B include introduction (1), explanation on the trial A (1) and trial B (1), trial B test (1), scoring (1), and hands check (1);
CANTAB = Cambridge Neuropsychological Test Automated Battery. Cognitive debriefings and international harmonization of the Arabic,
Russian, Bulgarian, and the Czech translations were not carried out and are therefore not reported. * Excluded from analyses, as translations
of the SF-36v2/-12v were obtained from Optum. CANTAB analyses are not presented here, because in the meantime only updated versions
from Cambridge Cognition can be used. Therefore, these are not available on the CENTER-TBI website.
At the semantic level, specifically, the term “(head, brain) injury” underwent semantic
changes across many languages. Frequently, “injury” was translated as “trauma” which
seemed more appropriate in the respective language contexts. Further semantic changes
concerned the choice of words, with the aim of capturing the original instruments as closely
as possible.
At the idiomatic/pragmatic level, the differences between translations comprised adap-
tations of English idioms and special phrases. For example, the question “How are you
satisfied with your ability to get out and about” from the QOLIBRI had to be explained,
as the idiom “get out and about” is phrased differently in many languages.
The cultural level included the use of specific pronominal forms, gender-appropriate
language, and the translation of specific terms lacking or seldom used in the culture of the
target language. Here, two tendencies were observed: (1) more informal gender-neutral
translations (especially in Northern European languages) and (2) more formal gender-
sensitive translations in other European languages and Hebrew. In addition, as already
expected after devising the conceptual list, differences occurred in the translation of the ex-
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planatory text of the GOSE-Q, which included an example of “playing bingo” among other
leisure activities. Since playing bingo is uncommon as a leisure activity in many countries,
many translating teams used a culturally more appropriate example such as “going out to
a restaurant”. For a detailed overview, see Supplementary Materials Table S1 online.
3.2. Cognitive Debriefings and Quality of Translations (Phases 4 and 5)
Overall, the average comprehension rates of the participants interviewed for each
instrument were above 90% for items and response categories and greater than or equal to
85% for the instructions (see Table 6). Some translations with lower comprehension rates
(e.g., the Swedish GOSE/GOSE-Q, the instructions of the Slovakian GOSE-Q, the instruc-
tions and responses of the French GOSE-Q, the instructions of the French PCL-5, and the
responses of the Slovakian QOLIBRI) required further revisions, which were carried out
in the next harmonization step. However, all comprehension rates were at least within
an acceptable range (25% to 75%) or above (≥75%), except for the instructions of the
Swedish version of the GOSE and the French version of the GOSE-Q, where all participants
commented on the wording, which was corrected.
The translational challenges determined in the cognitive debriefings for the ClinRO,
its questionnaire version, the PROMs on a linguistic (semantic, syntactic, and idiomatic),
and cultural level are summarized in Table 7, together with their solutions.
Linguistic and cultural differences can occur not only in the translation of PROMs
but also in the translation of PerfO instruments. The RAVLT can serve as an example
of the complexity of the translational and linguistic validation process. A good example
of some cultural differences is the word “church”, which is used less often in countries
where religious backgrounds other than Christianity are predominant. As a solution,
the use of the terms “mosque”, “synagogue”, “temple”, or “church” was implemented
for these translations. It was also noticed that one to two-syllable nouns were usually
used in the English version of the RAVLT, which is not the case in all languages. In the
Lithuanian, Russian, and Hungarian languages, for example, nouns generally have two or
more syllables, as reflected by the translated nouns. Since the number of syllables per word
may influence verbal memory, such language-specific characteristics need to be considered
for further multinational translation procedures concerning verbal memory.
3.3. Harmonization and Final Versions (Phases 6 and 7)
The harmonized versions underwent further revisions, depending on the complexity
and conceptual clarity of the instrument, the quality of the translations, and results of the
cognitive debriefings. When different opinions arose among the team members involved in
the final national and international harmonization, a consensus was sought resulting in the
most appropriate translations. Instrument developers were only contacted when problems
could not be solved, which only happened twice (for the GOAT and PCL-5). These versions
were reviewed by informed native speakers (members of the CENTER-TBI study) in the
different languages for final adjustments.
Table 8 provides an overview of the changes in coding the semantic, cultural, id-
iomatic/pragmatic, and syntactic/grammatical differences and issues between the first
harmonization and the final versions administered in the study. Most differences concerned
semantic and syntactic/grammatical changes. The changes contained improvements of in-
appropriate translations, consistent use of gender-appropriate language, and grammatical
issues (e.g., use of commas and spelling). Most of the issues involved the use of synonyms
or words that were initially translated literally from English into the target language but
that were not suitable in the context of this language.
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Table 6. Average comprehension rates per language and outcome instrument in the cognitive debriefings.
GOSE GOSE-Q PCL-5 QOLIBRI QOLIBRI-OS
No. Language N IN I R N IN I R N IN I R N IN I R N IN I R
1 Arabic (for Israel) - - - - - - - - - - - - - - - - - - - -
2 Bosnian/Croatian/Serbian 3 100% 100% 100% 6 83% 98% 88% 6 83% 85% 83% 6 67% 92% 100% 6 67% 81% 100%
3 Bulgarian - - - - - - - - - - - - - - - - - - - -
4 Czech - - - - - - - - - - - - - - - - - - - -
5 Danish * * * * 6 100% 100% 100% 6 100% 100% 100% * * * * * * * *
6 Dutch * * * * 3 100% 93% 95% 3 100% 95% 100% * * * * * * * *
7 Finnish * * * * 4 100% 98% 100% 6 100% 99% 100% * * * * * * * *
8 French * * * * 3 0% 93% 74% 3 33% 92% 98% * * * * * * * *
9 German * * * * 3 67% 100% 100% 3 100% 80% 100% * * * * * * * *
10 Hebrew 2 100% 100% 100% 4 100% 100% 100% 4 100% 100% 100% 4 88% 96% 100% 4 100% 100% 100%
11 Hungarian 2 100% 89% 100% 6 100% 100% 100% 6 100% 96% 100% 6 100% 100% 100% 6 100% 83% 83%
12 Italian 6 100% 91% 100% 6 100% 100% 100% 6 100% 100% 100% * * * * * * * *
13 Latvian 10 100% 100% 100% 10 100% 100% 100% 10 100% 100% 100% 10 100% 100% 100% 10 100% 100% 100%
14 Lithuanian 6 100% 100% 100% 6 100% 100% 100% 6 100% 100% 100% 6 100% 100% 100% 6 100% 86% 100%
15 Norwegian * * * * 6 100% 99% 87% * * * * * * * * * * * *
16 Romanian 3 100% 100% 100% 6 100% 100% 90% 6 100% 100% 100% 6 100% 100% 81% 6 100% 100% 100%
17 Russian (for Israel) - - - - - - - - - - - - - - - - - - - -
18 Slovakian 3 100% 86% 97% 6 67% 98% 100% 6 100% 94% 90% 6 92% 98% 100% 6 83% 100% 33%
19 Spanish 3 67% 99% 92% 6 67% 88% 90% 6 100% 81% 100% 10 100% 97% 100% 10 90% 83% 100%
20 Swedish 3 0% 96% 93% 6 83% 70% 76% 6 83% 92% 100% * * * * * * * *
Average 4 87% 96% 98% 5 85% 96% 94% 6 93% 94% 98% 7 93% 98% 98% 7 93% 92% 90%
Note: IN = instructions; I = items, R = item responses; — = no cognitive debriefing performed; * = already existing validated instruments not requiring cognitive debriefing. For the GOSE, mostly clinical
personnel were interviewed. Average = the overall average number of participants. Translations are available for the following languages, but no cognitive debriefings: Arabic, Bulgarian, Czech, and Russian.
N = number of cognitive debriefings performed, and average comprehension rates per instrument. Bold is for better readability.
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Table 7. Translational issues.
Instrument Language Type of Issue Text Element Description of the Problems by TargetLanguage Translators Solution
1
GOSE Italian Linguistic Instruction/heading: Date of injury Difficulties with translation of “injury” vs.“trauma” Term “trauma” selected
GOSE-Q
Finnish Cultural Item 7 (response 2): Looking after family
“Looking after family” seems to be rather
untypical for the Finnish society/culture
(exception: maternity or paternity leave,
homemaker)
Response extended by “e.g.,
maternity or paternity leave”
Hebrew Cultural
Item 9 (examples for social and leisure activities): going out to a pub
or club, visiting friends, going to the cinema or bingo, going out for
a walk, attending a football match, taking part in sport.
Playing bingo is rather untypical for
Hebrew society/culture
Term “bingo” replaced by “going
out to a restaurant”
Norwegian Cultural
Item 9 (examples for social and leisure activities): going out to a pub
or club, visiting friends, going to the cinema or bingo, going out for a
walk, attending a football match, taking part in sport.
Going to pubs is rather untypical for
Norwegian society/culture Term “pub” replaced by “café”
Swedish Linguistic
Item 12: As a result of your injury are there now problems in how
you get on with friends or relatives? (response 1): Things are still
much the same
The term “things” cannot be used in
Swedish in that way








Item 21: When you responded to the questions in this questionnaire,
were your answers in reference to the stressful experience which
caused your traumatic brain injury?
Difficulties with translation of the term
“injury” (“injury” vs. “trauma”, “head
injury”, or “accident”)
The closest meaning to the term
“brain injury” was selected in each
language
Arabic Linguistic Item 17: Being “superalert” or watchful or on guard? Difficulties with translation of “on guard” Corrected translation of “on guard”was implemented
RPQ Finnish Linguistic/Cultural
Introduction: We would like to know if you now suffer any of the
symptoms given below. Because many of these symptoms occur
normally, we would like you to compare yourself now with before
the accident.
Comment on the translation of the term
“you” (using pronominal courtesy form
would be more appropriate)
Pronominal courtesy form was
implemented
QOLIBRI Romanian
Linguistic Part F, item 5: Overall, how bothered are you by the effects of yourbrain injury?
Difficulties with translation of “overall” vs.
“in general”
Term “overall” replaced by “in
general”
Linguistic All items No female forms of verbs were available Female and male formsimplemented
GOAT Finnish Cultural Item 2a: Where are you now (city)? “Finland is mostly rural, there are a lot ofmunicipalities without towns” Term “city” replaced by “place”
Note: 1 The solution was provided after discussion between the patients, the healthy individuals, the core team and the translation teams in the target languages. Bold is for better readability.
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Table 8. Average (mean and median) number of differences between the first harmonized and the final internationally harmonized translations.
Average Number of Changes
ExamplesMean Median
Measure Text Elements No. S C I/P S/G S C I/P S/G
ClinRO, its questionnaire version, and a clinical amnesia rating
S: Use of synonyms to find the closest possible, but not a literal, translation, e.g.,
“injury” vs. “trauma”, “they” vs. “he/she”.
C: Use of courtesy (West, Middle, East, and Southern European languages) vs.
informal (especially Northern European languages) pronominal form and
gender-appropriate language (only emerged during harmonization in
some translations).
I/P: Use of appropriate expressions common for the target languages, e.g., “as
it appears”.
S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., word order and spelling.
GOSE
(10 translations)
In 11 31% 2% 10% 20% 18% 0% 9% 9%
I 19 22% 2% 1% 15% 21% 0% 0% 13%
R 15 9% 1% 1% 5% 7% 0% 0% 6%
S: Use of synonyms to find the closest possible, but not a literal, translation, e.g.,
“injury” vs. “trauma”.
C: Use of courtesy (West, Middle, East, and Southern European languages) vs.
informal (especially Northern European languages) pronominal form and
gender-appropriate language; use of examples suitable for the target language
countries, e.g., “playing bingo” vs. “going out to restaurant” (only emerged
during harmonization in some translations).
I/P: Use of appropriate translations of phrases “at least half as often” and “less
than half as often”.
S/G: Use of appropriate sentence structures, e.g., word order.
GOSE-Q
(16 translations)
In 2 107% 9% 7% 23% 50% 0% 0% 0%
I 14 11% 1% 0% 10% 4% 0% 0% 7%
R 42 7% 6% 1% 3% 2% 0% 0% 2%
S: Use of synonyms to find the closest possible, but not a literal, translation, e.g.,
“injury” vs. “trauma” or “accident”.
C: Use of courtesy (West, Middle, East, and Southern European languages) vs.
informal (especially Northern European languages) pronominal form and
gender-appropriate language (only emerged during harmonization in some
translations); use of time formats most common to the target language countries,
e.g., “am/pm” seem to be uncommon in most languages/countries.
I/P: Use of appropriate expressions common to the target languages in everyday
use, e.g., “Where are you now?”.
S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., word order and spelling.
GOAT
(16 translations)
In 8 10% 6% 3% 10% 0% 0% 0% 0%
I 13 16% 0% 7% 9% 8% 0% 0% 0%
R - - - - - - - - -
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Table 8. Cont.
Average Number of Changes
ExamplesMean Median
Measure Text Elements No. S C I/P S/G S C I/P S/G
PROMs *
S: -
C: Use of courtesy pronominal form and gender-appropriate language (only
emerged during harmonization in some translations).
I/P: -
S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., comma placement and spelling.
GAD-7
(2 translations)
In 1 0% 50% 0% 0% 0% 50% 0% 0%
I 7 0% 0% 0% 0% 0% 0% 0% 0%




S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., comma placement and spelling.
PHQ-9
(1 translation)
In 1 0% 0% 0% 0% 0% 0% 0% 0%
I 10 0% 0% 0% 20% 0% 0% 0% 20%
R 5 0% 0% 0% 0% 0% 0% 0% 0%
S: Use of synonyms to find the closest possible, but not a literal, translation, e.g.,
“stressful” or “disturbing” experience.
C: Use of courtesy pronominal form and gender-appropriate language (only
emerged during harmonization in some translations).
I/P: Use of appropriate expressions common to the target languages in everyday
use, e.g., “Being ‘superalert’ or watchful or on guard”.
S/G: Use of appropriate tense, sentence structures and grammar suitable for the




In 1 100% 7% 7% 47% 0% 0% 0% 0%
I 21 26% 1% 4% 14% 19% 0% 0% 14%
R 5 11% 0% 1% 7% 0% 0% 0% 0%
S: Use of synonyms to find the closest possible, but not a literal, translation of the
terms, e.g., “injury” vs. “trauma”, appropriate translation of “poor
concentrations” or “forgetfulness”.
C: Use of courtesy pronominal form (only emerged during harmonization in
some translations).
I/P: Use of appropriate expressions, e.g., in translating response category “no
more of a problem (than before)”.
S/G: Use of appropriate sentence structures, tense, and grammar suitable for the




In 1 123% 23% 23% 77% 0% 0% 0% 77%
I 17 6% 1% 3% 4% 6% 0% 0% 4%
R 5 9% 0% 3% 6% 0% 0% 0% 0%
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Table 8. Cont.
Average Number of Changes
ExamplesMean Median
Measure Text Elements No. S C I/P S/G S C I/P S/G
S: Use of synonyms to find the closest possible, but not a literal, translation of the
terms, e.g., “brain injury” vs. “trauma”, “How satisfied are you...” and “How
bothered are you...”.
C: Use of courtesy pronominal form and gender-appropriate language (only
emerged during harmonization in some translations).
I/P: Use of appropriate expressions, e.g., to be “in charge of your own life”.
S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., comma placement and spelling.
QOLIBRI
(8 translations)
In 7 14% 2% 0% 7% 14% 0% 0% 0%
I 37 10% 0% 1% 5% 9% 0% 0% 5%
R 5 20% 0% 0% 13% 10% 0% 0% 0%
S: Use of synonyms to find the closest possible, but not a literal, translation of the
terms, e.g., “brain injury” vs. “trauma”, “future prospects” vs. “plans for the
future”.
C: Use of courtesy pronominal form and gender-appropriate language (only
emerged during harmonization in some translations).
I/P: Use of appropriate expressions common in everyday use, e.g., “don’t hesitate
to ask for help”.
S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., comma placement and spelling.
QOLIBRI-OS
(8 translations)
In 1 25% 13% 38% 38% 0% 0% 0% 0%
I 6 13% 4% 2% 4% 6% 0% 0% 0%
R 5 5% 0% 3% 3% 0% 0% 0% 0%
PerfO *
S: Use of synonyms to find the closest possible, but not a literal, translation of the
instructions.
C: Use of courtesy pronominal form and gender-appropriate language (only
emerged during harmonization in some translations); use of language- and/or
culture-specific terms (e.g., “church” vs. “synagogue”).
I/P: Selection of suitable words more frequently used in everyday life, e.g., “tool”
or “cake”.
S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., comma placement and spelling especially in the instructions.
RAVLT
(16 translations)
In 5 81% 8% 9% 41% 30% 0% 0% 40%
I 45 3% 0% 2% 1% 3% 0% 0% 0%
R - - - - - - - - -
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Table 8. Cont.
Average Number of Changes
ExamplesMean Median
Measure Text Elements No. S C I/P S/G S C I/P S/G
S: Use of synonyms to find the closest possible, but not a literal, translation of the
instructions, e.g., “participant” or “examiner”.
C: Use of courtesy pronominal form and gender-appropriate language (only
emerged during harmonization in some translations).
I/P: Selection of suitable words more frequently used in everyday life, e.g., to be
“sure about” something.
S/G: Use of appropriate sentence structures and grammar suitable for the target
languages, e.g., comma placement and spelling, especially in the instructions.
TMT A/B
(14 translations)
In 6 14% 2% 5% 19% 0% 0% 0% 0%
I 38 0% 0% 0% 0% 0% 0% 0% 0%
R - - - - - - - - -
Note: No. = No. of text elements; In = average modifications between the first harmonization and the final version in instructions (average in %, i.e., number of differences relative to the total number of
the respective text elements divided by the number of translations); I = modifications in items; R = modifications in response categories (if applicable, otherwise “-“); S = syntactic level; C = cultural level;
I/P = idiomatic/pragmatic level; S/G = syntactical/grammatical level; ClinRO = clinician-reported outcome instrument; PROM = patient-reported outcome measures; PerfO = performance-based outcome
instruments; GOSE = Glasgow Outcome Scale—Extended; instructions of the GOSE include introduction (1), commentary on the questions (9), and scoring (1); GOSE-Q = Glasgow Outcome Scale—Extended
questionnaire version; instructions of the GOSE-Q include introduction and header (1) and explanatory example for the item 9; different types of responses (dichotomous yes/no, including extensions for
GOSE scoring) and polytomous item-related responses result in 42 elements; GOAT = Galveston Orientation Amnesia Test; the GOAT has no response categories; GAD-7 = Generalized Anxiety Disorder
7 Items Questionnaire; PHQ-9 = Patient Health Questionnaire 9; PCL-5 = Posttraumatic Stress Disorder Checklist; RPQ = Rivermead Post-Concussion Symptoms questionnaire; QOLIBRI = Quality of Life
after Brain Injury Scale; instructions of the QOLIBRI include introduction to the two parts (2) and five subsections (5); QOLIBRI-OS = Quality of Life after Brain Injury—Overall Scale; RAVLT = Rey Auditory
Verbal Learning Test; in the RAVLT, words are treated as items (5 × 15 = 45), there are no response categories; instructions of the RAVLT include introduction (1), explanations on the three trials (3), and the
summary table for evaluation of the test result (1); TMT-A/B = Trail-Making Test A, B; in the TMT-A/B, letters and numbers are treated as items, there are no response categories; instructions of the TMT-A,
B include introduction (1), explanation on the trial A (1) and trial B (1), trial B test (1), scoring (1), hands check (1); CANTAB = Cambridge Neuropsychological Test Automated Battery. * Excluded from analysis as
translations of the SF-36v2/-12v were obtained from Optum. CANTAB analyses are not presented here as in the meantime only updated versions from Cambridge Cognition can be used. Therefore, these are not
available on the CENTER-TBI website. Cognitive debriefings and international harmonization of the Arabic, Russian, Bulgarian, and the Czech translations were not carried out and are thus not reported.
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Considering the average (i.e., the mean) relative number of coded differences, the in-
struments involving the most changes were the RPQ, followed by the GOSE-Q and the
PCL-5. However, the main changes in the RPQ, and in the PCL-5 occurred only in a few
languages (Swedish, German, Danish, and Bosnian/Croatian/Serbian), which is reflected
in the average percentages. Based on the median, most changes were performed during
the harmonization of the GOSE-Q, followed by the RAVLT and the GOSE. For a detailed
overview, see Supplementary Materials Table S2 online.
In sum, these efforts resulted in linguistically validated translations into up to 20
languages of one ClinRO instrument, its questionnaire version, one clinical amnesia test,
six PROMs, and three PerfO instruments, including six CANTAB subtests.
4. Discussion
The translations of the 17 outcome measures into up to 20 languages and the linguistic
validations in up to 18 languages were achieved with input from over 150 international
collaborators. These translated instruments provide a basis for reliable and valid future TBI
outcome research and clinical practice, thereby facilitating data collection and comparisons
across 18 countries in Europe and Israel. Translated and linguistically validated versions
of the instruments used in the study are accessible in the public domain on the website of
CENTER-TBI (https://www.center-tbi.eu/ (accessed on 16 April 2021)).
Recommendations: The following recommendations resulting from our linguistic val-
idation work may be helpful for future international projects in the field of TBI and
related areas.
First, it is important to work with translators with linguistic expertise, as well as
expertise in the field of TBI, in addition to being native or fluent in English. In contrast to
the MAPI guidelines [25], we only seldom resorted to certified professional translators as
the professional translations had to be revised much more extensively in our study than
the others. Furthermore, similar to Swaine-Verdier et al. (2004) [28], we also attempted—
whenever possible—to integrate at least one person with a background in linguistics,
teaching, or administration in the translation process. These vocational groups were as-
sumed to be especially sensitized to the everyday use of language, comparable to the
language of the individuals later answering the instruments [28]. In addition, regardless
of the type of outcome measure (PROM, ClinRO, clinical amnesia test, or PerfO), it is
important to consider the linguistic concepts and cultural background of each country,
including the use of gender-appropriate language, courtesy, or informal pronominal forms,
and specific idiomatic and pragmatic terms. Instruments with items using different and/or
item-specific response formats and more detailed instructions do require more work com-
pared with instruments consisting only of a few items with a standard Likert response
scale. The translation and linguistic validation of clinical rating scales, such as the GOSE,
were particularly time-consuming and complex. Detailed standardized training of raters is
also recommended for this type of clinical scale, to enhance the comparability of the ratings.
Second, besides the selection of translators, the integration of extensive international
harmonization panels and the good to excellent psychometric properties of the translated
and linguistically validated PROMs described in von Steinbuechel et al. [32], as well as
in van Praag et al. [54] and in Plass et al. [55], underline the quality of our translations
of the instruments based on the procedure applied. Furthermore, we found face-to-face
or video conferences very helpful during this procedure to enhance coherence across all
languages. Visiting some translating country centers that participated in the linguistic
validation procedure in person also served to intensify and ameliorate the process.
Third, as an understanding of the importance, implications, and intense workload
of linguistic validation procedures is still underrepresented in the field of TBI research,
more resources should be allocated to this type of undertaking. For future international
multidimensional outcome studies on TBI, we wish to provide a solid basis for linguistic
validation and its funding.
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Fourth, the issue of commercial ownership of instruments is one that public funding
bodies such as the EU and the National Institutes of Health (NIH) should consider before
designating instruments as recommended data elements. While the costs involved in
using such commercial instruments may not be an insurmountable burden in high-income
countries, they may be extremely challenging in low- and middle-income countries. The SF-
12v2, SF-36v2, and the CANTAB are only available on a commercial basis. All translations
of the QOLBRI and the QOLIBRI-OS instruments described in this manuscript are freely
available for academic use from www.center-tbi.eu (accessed on 16 April 2021) and https:
//qolibrinet.com (accessed on 16 April 2021). In addition, translations of these instruments
developed within the CENTER-TBI project (Arabic, Bulgarian, Bosnian/Croatian/Serbian,
Hebrew, Hungarian, Latvian, Lithuanian, Romanian, Russian, Slovakian, and Spanish)
are also free for commercial use. All other translations of these instruments that preceded
the CENTER-TBI project are not covered by CENTER-TBI agreements; they are free for
academic research, but not for commercial use. For further information and potential
(commercial) use, please access https://qolibrinet.com (accessed on 16 April 2021).
Fifth, many of the outcome instruments are available in a wide range of versions,
the existence of which is not obvious. Resources, therefore, need to be used to identify
appropriate versions ensuring the comparability of data.
Sixth and final, as the translation and linguistic validation procedures were labor-
and resource-intensive, they could only be accomplished thanks to the dedication and
using the personal resources of contributing CENTER-TBI participants, investigators, and
MC members.
Overall, the freely available ClinRO, its questionnaire version, a clinical amnesia test,
PROMs, and PerfOs and the results of the present study provide many opportunities
for future translations and linguistic validations in other languages. The psychometric
validation of the PROMs [32] in different languages establishes a reliable basis for national,
international, and multicenter studies in the field of TBI.
Limitations. The translation and linguistic validation procedure described in the
present study mainly followed the recommendations of MAPI [25] and ISPOR [26,27],
with some adaptations in terms of the conceptual analyses, selection of translators, and the
number of translations and cognitive debriefings. In contrast to these recommendations,
we only contacted developers for the conceptual analysis of the original instruments
when difficulties occurred with the concept description or if difficulties arose during the
harmonization. Translators did not need to provide a language certificate but needed to
be native speakers, fluent in English, experienced in the care of patients in the field of
TBI, and preferably in outcome assessment. The effectiveness of this type of selection
of professionals was also reflected in the good to excellent psychometric quality of the
translations [53–55]. As the labor-intensive procedures required a pragmatic approach with
an efficient use of limited resources, only one formal forward translation was carried out
for the non-core or not additionally prioritized instruments (i.e., GOAT, GAD-7, PHQ-9,
RPQ, TMT-A, B, RAVLT, and CANTAB).
However, we tried to compensate for potential deficits by means of intense iterative
reviews, revisions, and international harmonization. Concerning the cognitive debriefings
performed, we interviewed at least two clinicians, three-to-five laypersons, and three to
five TBI patients, instead of the minimum five described by MAPI [25], which was an
effective way of coping with the shortage in some countries (centers) of TBI patients willing
to participate in the cognitive debriefings.
Finally, we decided to delay publication until the data and results of psychometric
analyses of the translated instruments were available [32], which required completion of
enrolment and six-month outcome assessment (2018) and subsequent data curation and
analysis (2020 to 2021).
Future perspectives. Future research should perform cognitive debriefings and interna-
tional harmonization of the Arabic, Russian, Bulgarian, and Czech translations, which have
not been carried out. In the next step, the psychometric characteristics and measurement
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invariance of the concepts used in the different instruments should be a topic for future
research [56–58].
5. Conclusions
Linguistically validated translations in up to 20 languages were produced for one
ClinRO (GOSE) and its questionnaire version (GOSE-Q), one clinical amnesia test (GOAT),
six PROMs (GAD-7, PHQ-9, PCL-5, RPQ, QOLIBRI, QOLIBRI-OS), and three PerfO instru-
ments (RAVLT, TMT-A,B) and the CANTAB with six separate subtests for individuals after
TBI. The translations of the outcome instruments, in so far as they are in the public domain,
are available on the CENTER-TBI homepage (https://www.center-tbi.eu/, accessed on 16
April 2021).
The description of the linguistic validation process of these instruments may provide
the basis for future linguistic and psychometric validations for national and multinational
cross-cultural TBI outcome studies. The availability of these instruments with good to ex-
cellent psychometric properties in the field of TBI [32] in the most widely spoken languages
in Europe and Israel may facilitate and improve outcome research and clinical evaluation
of individuals after TBI in the future.
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Appendix A. Linguistic Validation Group
Name Affiliation
Abu Shkara Ramiz Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Alshafai Nabeel Neurosurgical Academy, Toronto, Canada
Andelic Nada
Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway and
Faculty of Medicine, Institute of Health and Society, Research Centre for Habilitation and
Rehabilitation Models and Services (CHARM), University of Oslo, Oslo, Norway
Azouvi Philippe Physical and Rehabilitation Medicine, Hospital Raymond Poincaré, Garches, France
Bachvarova Maya
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Bakx Wilbert Department of brain injury, Adelante, Adult rehabilitation, Hoensbroek, The Netherlands
Bar Sapir Peleg no affiliation
Björkdahl Ann
Ersta Sköndal Bräcke University College, Institute of Social Science, campus Bräcke, Gothenburg,
Sweden
Branca Enrica
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Brazinova Alexandra Faculty of Medicine, Comenius University, Bratislava, Slovak Republic
Chatelle Camille Louvain Bionics, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium
Dahyot-Fizelier Claire
Department of Anesthesia and Intensive Care, University Hospital of Poitiers, INSERM U1070,
University of Poitiers, Poitiers, France
Del Bianco Silvia Neurointensive Care Unit, San Gerardo Hospital Monza, Monza, Italy
Furmanov Alex Neurosurgery ICU, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Godbolt Alison University Department of Rehabilitation Medicine Stockholm, Danderyd Hospital, Sweden
Gürlich Robert General University Hospital Kralovske Vinohrady, Prague, Czech Republic
Hedenäs Anna
University Department of Rehabilitation Medicine, Danderyd Hospital, Acquired Brain Injury Unit,
Daycare, Stockholm, Sweden
Hoang Stéphane
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
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Name Affiliation
Kanuscak Martin
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Karan Mladen Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway
Kondziella Daniel Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Koskinen Sanna Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finnland
Laleva Maria Department of Neurosurgery, University Hospital Pirogov, Sofia, Bulgaria
Levi Leon Rambam Healthcare Campus, Haifa, Israel
Liebertau Pia
Klinik IV, Klinikum Osnabrück, Germany, and Institut für Ethik und Geschichte der Medizin,
University Medical Center Göttingen, Göttingen, Germany
Lundgaard Soberg Helene Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway
Martino Costanza Dipartimento Chirurgico e Grandi Traumi, Ospedale M. Bufalini, Cesena, Italy
Menovsky Tomas Department of Neurosurgery, Antwerp University Hospital, Antwerp, Belgium
Milinkovic Sladana Clinical Center of Vojvodina, Novi Sad, Serbia
Mondello Stefania
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of
Messina, Italy
Nelson David Department of Physiology and Pharmacology, Karolinska Universitetssjukhus, Solna, Sweden
Oistensen Holthe Oyvor Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway
Pestovskaya Natalia
Burdenko National Medical Research Center of Neurosurgery (NN Burdenko NMRCN),
Moscow, Russia
Pfeiffer Anna
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Popescu Codruta
Department of Practical Abilities, Human Science, University of Medicine and Pharmacy Iuliu
Hatieganu, Cluj-Napoca, Romania
Potapov Aleksandr
Burdenko National Medical Research Center of Neurosurgery (NN Burdenko NMRCN),
Moscow, Russia
Poulsen Ingrid
Department of Neurorehabilitation, TBI Unit, Rigshospitalet, Denmark and Research Unit Nursing
and Health Care, Health, Aarhus University, Denmark
Radoi Andreea Clinical Research Office at BarcelonaBeta Brain Research Center, Barcelona, Spain
Ragauskas Arminas Health Telematics Science Institute, Kaunas University of Technology, Kaunas, Lithuania
Ramin Irina
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Ramin Petr
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Ramin Stanislav
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Reggi Valeria University of Brescia, Brescia, Italy and University of Bologna, Bologna, Italy
Reith Florence Department of Neurosurgery, Sir Charles Gairdner Hospital, Perth, WA, Australia
Ribbers Gerard
Department of Rehabilitation Medicine, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, the Netherlands
Rocka Saulius Clinic of Neurology and Neurosurgery, Vilnius University, Vilnius, Lithuania
Rosenlund Sorensen
Christina
Department of Neurosurgery, Odense University Hospital, Odense, Denmark
Rosenthal Guy Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Sahuquillo Juan Department of Neurosurgery, Vall d’Hebron University Hospital, Barcelona, Spain
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Name Affiliation
Schäfer Kaja J. Department of Pediatrics, Klinikum Bremerhaven-Reinkenheide gGmbH, Bremerhaven, Germany
Schou Rico Neuroanesthesiology and -Intensive Care, University Hospital of Odense, Odense, Denmark
Siponkoski Sini-Tuulu
Cognitive Brain Research Unit, Department of Psychology and Logopedics, University of Helsinki,
Helsinki, Finnland
Skandsen Toril
Institute of Neuromedicine and Movement sciences Norwegian University of Science and
Technology Specialist in Physical and Rehabilitation Medicine St. Olavs Hospital, Trondheim
University Hospital, Norway
Skoett Skare BruunMarie
Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of
Copenhagen, Denmark
Skowroneck Lukas
Department of Languages, Literature and Communication, University of Utrecht, Utrecht,
the Netherlands
Sokkanen Sanna E. South Karelia Social and Health Care District, University of Jyväskylä, Jyväskylä, Finnland
Sonne E. Morten
Centre of Head and Orthopaedics, Department of Anaesthesiology, Copenhagen University Hospital,
Rigshospitalet, Copenhagen, Denmark
Steinbusch Catherine Adelante Rehabilitation Centre Valkenburg, Valkenburg, the Netherlands
Stocchetti Nino
Dipartimento Fisiopatologia e Trapianti, Fondazione IRCCS Cà Granda Ospedale Maggiore
Poloclinico, Milan, Italy
Tamir Idit Neurosurgery Department, Rabin Medical Center Petach Tikva, Petach Tikva, Israel
Tenovuo Olli Turku Brain Injury Centre, University of Turku and Turku University Hospital, Turku, Finnland
Teunissen Charlotte Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Theodorou Konstantina
Institute for Medical Psychology and Medical Sociology, University Medical Center Göttingen,
Göttingen, Germany
Turcsányi Ditta English and Hungarian as a Foreign Language Teacher
Valeinis Egils Neurosurgery Clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia
Van der MerschNils Université Libre de Bruxelles, Bruxelles, Belgium
van Laake-Geelen
Charlotte
Adelante Centre of Expertise in Rehabilitation and Audiology, Hoensbroek, The Netherlands
Van Praag Dominique
Department of Psychology, Antwerp University Hospital, Edegem and University of Antwerp,
Antwerp, Belgium
Vargiolu Alessia School of Medicine and Surgery, University of Milano—Bicocca, Milan, Italy
Velinov Nikolay
Department of Neurosurgery for Adults, Clinics of Neurosurgery, University Hospital Pirogov,
Novi Sad, Serbia
Vilcinis Rimantas
Department of Neurosurgery, Hospital of Lithuanian University of Health Sciences,
Kaunas, Lithuania
Vulekovic Petar Clinic of Neurosurgery, Clinical Center of Vojvodina, Novi Sad, Serbia
Appendix B. Instruments Administered in the CENTER-TBI Study
Appendix B.1. Clinician-Reported Outcome Assessments (ClinRO), Its Clinical Version and a
Clinical Amnesia Test
Glasgow Outcome Scale Extended (GOSE-Interview) [37]. This clinical rating evaluates
patients’ functional status and level of disability. The GOSE consists of 19 items with
both dichotomous and polytomous responses measuring different domains (consciousness,
independence at home and outside home, work, social and leisure activities, family and
friendships, return to normal life, and epilepsy). Functional outcome is rated by a clinician
on an eight-point scale (1 = dead, 2 = vegetative state, 3/4 = lower/upper severe disability,
5/6 = lower/upper moderate disability, and 7/8 = lower/upper good recovery).
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Glasgow Outcome Scale Extended—Questionnaire version (GOSE-Q) [38]. This question-
naire addresses similar aspects to the GOSE interview in a format that a patient can answer
with or without help, or a caretaker can complete. The GOSE-Q consists of 14 items with
different response formats (from “yes”/“no” to specifically item-related rating scales and
response categories). In the CENTER-TBI study, the GOSE-Q was used for data collection
via mail or during a visit. The allocation to the respective functional status categories
according to the GOSE definition was performed centrally.
Galveston Orientation Amnesia Test (GOAT) [39]. This standardized evaluation based
on patient responses assesses whether an individual suffers from post-traumatic amnesia
(PTA). It comprises ten items measuring orientation, memory for the first event that the
participant can recall after the injury (anterograde amnesia), and memory for the last event
that the participant can recall from before the injury (retrograde amnesia). The instrument
is administered by clinical personnel.
Appendix B.2. Patient-Reported Outcome Measures (PROMs)
Generalized Anxiety Disorder 7 (GAD-7) [40]. With seven items, this self-report tool
assesses symptoms of generalized anxiety disorder with a recall period of the past two
weeks. The GAD-7 applies a four-point Likert scale (from 0 “not at all” to 3 “nearly
every day”).
Patient Health Questionnaire 9 (PHQ-9) [41]. This short self-report instrument captures
presence and severity of major depression using nine items based on the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) [59], criteria with a recall
period of the past two weeks.
Posttraumatic Stress Disorder Checklist (PCL-5) [42]. This self-report scale evaluates
20 posttraumatic stress disorder (PTSD) symptoms with a recall period of one week at
the two-week assessment and a recall period of a month for later assessments. The rat-
ing is based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition
(DSM-5) [60] and applies a five-point Likert scale (from 0 “not at all” to 4 “extremely”).
Rivermead Post-Concussion Symptoms Questionnaire (RPQ) [43]. This self-report ques-
tionnaire measures 16 post-concussion symptoms after TBI applying a five-point Likert
scale (from 0 “not experienced at all” to 4 = “a severe problem”). Individuals rate how
much they suffered from the following symptoms over the last 24 h compared with their
condition before the injury: headaches, dizziness, nausea and/or vomiting, noise sensitiv-
ity, sleep disturbance, fatigue, irritability, depression, frustration, forgetfulness and poor
memory, poor concentration, slow thinking, blurred vision, light sensitivity, double vision,
and restlessness. Two additional open questions assess further difficulties experienced
after TBI which should be rated on the same scale as other symptoms.
Quality of Life after Brain Injury Scale (QOLIBRI) [44,45]. This is a disease-specific
instrument for individuals after TBI, assessing HRQOL using 37 items on a five-point Likert
scale (from 0 “not at all” to 4 “very”). Based on these items, the following six domains
are evaluated: cognition, self, daily life and autonomy, social relationships, emotions,
and physical problems.
Quality of Life after Brain Injury—Overall Scale (QOLIBRI-OS) [46]. The QOLIBRI-OS is
a short screener of disease-specific HRQOL after TBI. It comprises six items, which measure
physical conditions, cognition, emotions, daily life and autonomy, social relationships,
and current and future prospects, respectively. The QOLIBRI-OS applies a five-point Likert
scale (from 0 “not at all” to 4 “very”).
Additionally, two generic PROMs assessing the subjective health status—the 36-item
Short Form Health Survey—Version 2 (SF-36v2) [47] and the 12-item Short Form Survey—
Version 2 (SF-12v2) [48]—were administered in the CENTER-TBI study. Both measures had
already been translated into the target languages and had to be purchased from Optum [52]
for one-time use.
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Appendix B.3. Performance-Based Outcome Instruments (PerfO)
Cambridge Neuropsychological Test Automated Battery (CANTAB) [49]. The CANTAB is a
computer-based, mainly language-independent test battery well suited for administration
in multinational settings. The license to use this battery is made available by Cambridge
Cognition [61]. Although the CANTAB is language-independent and is administered
by trained personnel, participants should receive standardized information on the test
procedure. The instructions are provided for each of six subtests and contain explana-
tions and examples for each task (e.g., instructions for practice trials, hints for keyboard
usage, prompts, etc.). To ensure the validity of the GOAT translations, this information
should be equivalent across the languages. Therefore, the test instructions of the following
six CANTAB tests, selected for the application in the CENTER-TBI study, needed to be
translated into most languages:
1. Reaction Time (RTI)—The RTI is designed to measure motor and mental response
speed, movement time, reaction time, response accuracy, and impulsivity.
2. Spatial Working Memory (SWM)—This test measures the subject’s ability to remem-
ber spatial information and requires retention and manipulation of visual-spatial
information, working memory, and executive functions.
3. Paired Associate Learning (PAL)—This test assesses conditional learning and episodic
visual memory and is primarily sensitive to processes associated with the medial
temporal lobe.
4. Rapid Visual Processing (RVP)—The RVP captures visual sustained attention, be-
ing sensitive to dysfunctions in the parietal and frontal lobe brain areas.
5. Attention Switching Task (AST)—As a measure of cued attentional set-shifting this
test captures executive functioning and cognitive flexibility.
6. Stockings of Cambridge (SOC)—Spatial planning and spatial working memory are
assessed with this measure of frontal-lobe functioning.
Rey Auditory Verbal Learning Test (RAVLT) [50]. This memory word list evaluates a
range of memory functions, including verbal memory, shorter and longer retention of
information and learning, and is administered by trained examiners. The instrument
consists of two lists (A and B form) comprising 15 words, respectively. In total, there were
four versions of the RAVLT, each with two different word lists. Three versions of two
RAVLT word lists were administered in the CENTER-TBI study (lists 1 to 3 in 2-week,
3-month, and 6-month outcome assessments, respectively, and lists 3 to 1 at 6-, 12-, and
24-month outcome assessments, respectively).
Trail-Making Test A, B (TMT-A, B) [51]. This test measures executive functions, such as
visual attention, speed, and mental flexibility, and consists of two parts (A+B). The TMT-A
consists of 25 circles filled with numbers (1 to 25), which are to be connected in ascending
order (from 1 to 2, from 2 to 3, etc.). The TMT-B includes both numbers (1 to 13) and letters
(A to L), which are to be connected in ascending order from a letter to a number (i.e., from 1
to A, from A to 2, from 2 to B, etc.). In both tests, the time is measured, and the result is
reported in seconds.
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